Erschienen in:
27.10.2017 | Melanomas
Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases
verfasst von:
Lodewijka H. J. Holtkamp, MD, Shu Wang, MBBS, James S. Wilmott, PhD, Jason Madore, MSc, Ricardo Vilain, MBBS, PhD, FRCPA, John F. Thompson, MD, FRACS, FACS, Omgo E. Nieweg, MD, PhD, Richard A. Scolyer, MD, FRCPA, FRCPath
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2017
Einloggen, um Zugang zu erhalten
Excerpt
We thank Madu and colleagues for their interest in our article on the incidence of non-sentinel lymph node involvement in melanoma patients with minimal tumor burden in sentinel nodes.
1 There are a number of issues raised in their letter that we consider deserve further comment. Madu et al.’s statement that benefit from completion node dissection is negligible because only 0.29% of the lymph nodes were tumor-positive is misleading because it does not touch the heart of the matter, which is that additional metastatic nodal disease was found in one of our twenty patients i.e. 5%! They quote a large study in which patients with a minimal sentinel node metastasis did not undergo a node dissection but were observed for 5 years.
2 In fact, the 5% of patients who developed nodal recurrence during follow up in that study concurs with our finding. So, there is agreement on the 5% risk of additional nodal involvement in melanoma patients with minimal tumor burden in their positive sentinel node. …
